DS
PRAX icon

David Shaw’s Praxis Precision Medicines PRAX Stock Holding History

David Shaw’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.67M Hold
5,000
– – ﹤0.01% 3351
2026
Q1 		$1.61M Hold
5,000
– – ﹤0.01% 3086
2025
Q4 		$1.47M Buy
+5,000
New +$931K ﹤0.01% 3279

Other funds holding PRAX

JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

David Shaw's PRAX Position: Q2 2026 in Review

David Shaw opened a new position in Praxis Precision Medicines (PRAX) in Q2 2026: 5,140 shares worth $1.72M. The stake represents ﹤0.01% of the portfolio and ranks #3334 among its holdings. This is a return to the name: David Shaw previously reported a position in PRAX as recently as Q4 2025.

David Shaw first reported a position in PRAX in Q2 2021 and has held it in 12 quarters since. The position peaked at $11M in Q4 2025. 307 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

  • David Shaw held 5,140 shares of Praxis Precision Medicines worth $1.72M as of Q2 2026.
  • Praxis Precision Medicines was a new David Shaw position in Q2 2026.
  • Praxis Precision Medicines made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #3334 holding.
  • David Shaw first reported a position in Praxis Precision Medicines in Q2 2021 and has held it in 12 quarters since.
  • David Shaw's Praxis Precision Medicines position peaked at $11M in Q4 2025.
  • 307 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.